Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (NYSE: TMO) is frequently in the news as the world leader in serving science, with disclosures and press releases covering its activities across life sciences, diagnostics, analytical instruments and pharma services. News about Thermo Fisher often highlights how the company’s technologies and services support customers in accelerating life sciences research, solving analytical challenges, improving laboratory productivity, enhancing diagnostics and enabling the development and manufacture of life‑changing therapies.
Recent Thermo Fisher news includes strategic collaborations, regional investments, product clearances, capital allocation decisions and financing transactions. The company announced a collaboration with NVIDIA to power AI‑based solutions and laboratory automation, pairing its scientific instruments and lab software with NVIDIA’s AI infrastructure to increase automation, accuracy and speed in laboratories. It also reported an expansion of its bioprocessing capabilities in Asia through Bioprocess Design Centers in Incheon, Hyderabad and Singapore, aimed at supporting the region’s biopharmaceutical industry.
Thermo Fisher’s news flow also covers regulatory and clinical milestones, such as 510(k) clearance in the United States for the EXENT System, an automated platform designed as an aid in the diagnosis of multiple myeloma and related disorders. Financial and corporate updates include announcements of euro‑denominated and U.S. dollar‑denominated senior note offerings, a $5 billion share repurchase authorization, quarterly dividends, and agreements and completions related to acquisitions such as Solventum Corporation’s purification and filtration business and Clario Holdings, Inc.
Visitors to this TMO news page can review a stream of these company‑specific developments, from earnings‑related announcements and conference presentations to leadership changes and strategic initiatives disclosed in press releases and SEC‑linked communications.
Thermo Fisher Scientific reported strong second quarter results for 2022, with revenue reaching $10.97 billion, marking an 18% increase. The company achieved GAAP diluted EPS of $4.22 and adjusted EPS of $5.51. Core organic revenue growth was 13%, supported by $0.63 billion in COVID-19 testing revenue. Significant product launches included the Gibco CTS TrueCut Cas9 Protein and the Phadia 2500+ series. The company expanded its production capacity to meet rising demand in high-growth markets, contributing to a strong performance outlook.
Mercy BioAnalytics has appointed Dr. Dawn Mattoon as Chief Operating Officer, effective immediately. With a 20-year career in biotechnology, Dr. Mattoon previously led Clinical Diagnostics at Quanterix Corporation, overseeing the launch of COVID-19 tests and securing FDA Breakthrough Device designations for Alzheimer's and Multiple Sclerosis diagnostics. Her expertise will bolster Mercy's efforts in commercializing the Mercy Halo™ early cancer detection platform, which targets hard-to-detect ovarian and lung cancers. CEO Paul Blavin expressed optimism for growth under her leadership.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per share, approved by its Board of Directors on July 7, 2022. The dividend is set to be paid on October 14, 2022, to shareholders on record as of September 15, 2022. With annual revenues around $40 billion, Thermo Fisher continues to support scientific progress through innovative technologies and services.
Thermo Fisher Scientific Inc. (NYSE: TMO) will release its financial results for Q2 2022 on Thursday, July 28, 2022, before the market opens. A conference call will follow at 8:30 a.m. EDT to discuss financial performance and future expectations.
The company reported an annual revenue of approximately $40 billion, supporting various scientific endeavors globally.
Relation Therapeutics has successfully raised $25 million in a seed financing round led by DCVC and Magnetic Ventures. The new capital will help expand its platform that integrates active-graph machine learning with single-cell analysis to accelerate drug discovery, targeting diseases with limited treatment options.
Dr. David Roblin and Dr. Lindsay Edwards have joined the company as CEO and CTO, respectively. The funding aims to enhance the understanding of disease biology and improve therapeutic outcomes.
Thermo Fisher Scientific (NYSE:TMO) has unveiled new mass spectrometry instruments, workflows, and software at the 70th ASMS Conference from June 5-9, 2022, in Minneapolis. These innovations aim to enhance analytical insights and accelerate biopharma development. Notable products include the Thermo Scientific Direct Mass Technology and the AccelerOme Automated Sample Preparation Platform, designed to improve reproducibility and detail in biotherapeutic analysis. Additionally, cross-industry collaboration with TransMIT GmbH aims to enhance spatial multi-omics applications.
Thermo Fisher Scientific (NYSE:TMO) released its annual Corporate Social Responsibility report, emphasizing progress in environmental, social, and governance (ESG) objectives. Key highlights include a 12% reduction in Scope 1 and 2 emissions since 2018, commitment to net-zero emissions by 2050, and an increase in spending with underrepresented businesses from $1.3 billion to $2.0 billion. The company also engaged over 100,000 students in STEM programs and logged 105,000 volunteer hours globally.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per common share on May 18, 2022. The dividend will be payable on July 15, 2022, to shareholders of record as of June 15, 2022. The company, a leading name in serving science, reported an annual revenue of approximately $40 billion. Thermo Fisher aims to enhance health, safety, and environment through its extensive range of innovative technologies and services.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced that its CEO, Marc N. Casper, will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 12:20 p.m. EDT. The presentation will be accessible via a webcast on the company's Investor Relations page. Thermo Fisher Scientific reported annual revenues of approximately $40 billion, focusing on making the world healthier, cleaner, and safer through innovative technologies and pharmaceutical services. For more details, visit www.thermofisher.com.
Thermo Fisher Scientific reported first-quarter 2022 revenue of $11.82 billion, achieving 19% growth year-over-year. The company's GAAP diluted EPS was $5.61, down from $5.88 in Q1 2021, while adjusted EPS rose to $7.25. The results highlighted 16% core organic growth and $1.68 billion from COVID-19 testing. The launch of innovative products and a 15-year collaboration with Moderna for mRNA vaccine manufacturing were key highlights. The company also repurchased $2.0 billion in stock and increased its dividend by 15%.